The strong Q2 beat and reiterated guidance confirm WAKIX's commercial momentum, while the BP-205 Phase 1 data de-risks the pipeline. Traders should watch for the October 22, 2026 ANDA litigation closing arguments and the Q4 2026 BP-205 MAD data readout as the next key catalysts.
Price Chart
Executive Summary
Harmony Biosciences reported record Q2 2026 WAKIX net revenue of $261.3M (+30% YoY), with GAAP diluted EPS of $1.28 beating the $1.15 consensus by 11.5%. The company reiterated full-year 2026 WAKIX net revenue guidance of $1.0B-$1.04B and disclosed encouraging Phase 1 SAD data for its orexin-2 agonist BP-205, supporting a potential best-in-class profile. The strong beat on both revenue and EPS, combined with a reiterated guidance and positive pipeline data, is a clear positive for the stock.
Key Financial Metrics
Key Facts
- Q2 2026 WAKIX net revenue of $261.3M, up 30% YoY from $200.5M
- GAAP diluted EPS of $1.28, beating consensus of $1.15 by 11.5%
- Net income of $75.4M, up 90% YoY from $39.8M
- Reiterated 2026 WAKIX net revenue guidance of $1.0B-$1.04B
- Cash, cash equivalents and investments of $962.5M as of June 30, 2026
- Phase 1 SAD data for BP-205 shows favorable PK and safety/tolerability profile; MAD data expected Q4 2026
- Pitolisant GR NDA accepted by FDA with target PDUFA date of April 1, 2027
- Average patients on WAKIX increased by 450 to 8,950 in Q2
Financial Impact
Q2 revenue beat consensus by ~$8M (3.2%); EPS beat by $0.13 (11.5%); net income doubled YoY to $75.4M
Risk Factors
- ANDA litigation for WAKIX patents with closing arguments scheduled for October 22, 2026
- BP-205 is still in early-stage development with Phase 2 trials not starting until mid-2027
- Cost of product sold increased to 24.2% of revenue from 19.0% due to new royalties
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-090086 |
| Document: hrmy-20260804x8k.htm | 0001104659-26-090086 |
| Document: hrmy-20260804xex99d2.htm | 0001104659-26-090086 |
| Document: 0001104659-26-090086-index-headers.html | 0001104659-26-090086 |
| Document: 0001104659-26-090086-index.html | 0001104659-26-090086 |
| Document: 0001104659-26-090086.txt | 0001104659-26-090086 |
| 8-K Data (Synthetic) | 0001104659-26-090086 |
Track record
20 reports on HRMY
2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +14.82% at T+20 after the Jul 16, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $33.21 Now $32.96 −0.75% settles Dec 15
- Nov 4, 202612d ago 8-K Bearish 5/10 No price data
- Nov 4, 202612d ago Press Release Bearish 5/10 Entry $34.42 Now $32.96 +4.23% settles Dec 3
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $37.02 Now $32.96 −10.97% settles Dec 2
- Oct 30, 202617d ago 8-K/A Neutral 3/10 Entry $37.91 Now $32.96 −13.06% settles Dec 1
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $38.50 Now $32.96 −14.39% settles Nov 25
- Oct 13, 20264w ago 8-K Neutral 3/10 Entry $37.03 to $33.55 Now $32.96 −10.99% ▼ −9.40% −5.79% vs SPY
- Oct 1, 20266w ago Press Release Neutral 3/10 Entry $39.57 to $38.59 Now $32.96 −16.70% ▼ −2.48% −3.18% vs SPY
- Aug 4, 202614w ago 8-K Bullish 7/10 Viewing No price data
- Aug 4, 202614w ago Press Release Bullish 6/10 Entry $38.78 Now $32.96 −15.01% No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers